This site is intended for healthcare professionals

European Medicines Agency validates application for tepotinib for the treatment of advanced NSCLC with METex14 skipping alterations.- Merck KGaA.

Read time: 1 mins
Last updated:27th Nov 2020
Published:27th Nov 2020
Condition: NSCLC / MET
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest